Melanoma

Explore a Clinical Trial for Melanoma

Merck is passionate about improving health. We are committed to accelerating every step in the journey in our quest to bring treatment options to people with cancer. 

Clinical trials for melanoma are underway and currently enrolling patients. If you have patients with melanoma, you may want to consider a Merck Oncology Clinical Trial.

To see if your patients qualify for one of these trials, contact our clinical trial information center at 1-888-577-8839. If you are interested in partnering with us as an investigator, call 1-800-290-4339.

8

Active Trials

4

Trials Recruiting

68

US Trial Locations

Explore Active Clinical Trials

Trial Description Trial Number Condition Phase Status
Safety and Efficacy Study of Pembrolizumab Combined With Lenvatinib as First-line Intervention in Adults With Advance Melanoma
7902-003 Malignant Melanoma Phase 3 Recruiting
Efficacy and Safety of Lenvatinib Plus Pembrolizumab for Advanced Melanoma in Anti-Programmed Death-1/Programmed Death-Ligand 1 -Exposed Participants
7902-004 Advanced Melanoma Phase 2 Active, not recruiting
Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma
716 Melanoma Phase 3 Recruiting
Study to Evaluate the Safety and Efficacy of Pembrolizumab as First Line Therapy in Participants With Advanced Merkel Cell Carcinoma
913 Merkel Cell Carcinoma Phase 3 Recruiting
A Study of the Safety and Efficacy of Pembrolizumab in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma
022
  • Melanoma
  • Solid Tumors
Phase 1/Phase 2 Active, not recruiting
Safety and Tolerability of Pembrolizumab + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma
029
  • Renal Cell Carcinoma
  • Melanoma
Phase 1/Phase 2 Active, not recruiting
Study of Pembrolizumab Versus Placebo After Complete Resection of High-Risk Stage III Melanoma
054 Melanoma Phase 3 Active, not recruiting
An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Patients With High-Risk Melanoma
942 Melanoma Phase 2 Recruiting
Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of Pembrolizumab Compared to Ipilimumab in Participants With Advanced Melanoma
006 Melanoma Phase 3 Completed